Clofibrate is an established hypolipidemic drug which lowers plasma triglyceride concentrations. The mechanism of its triglyceride lowering action is still uncertain. However, it has been shown that the drug lowers plasma FFA concentration (Rifkind 1966 ). It has also been shown to inhibit lipolysis in rat (Barrett 1966 , Carlson et al. 1972 and human (D'Costa & Angel 1975) adipose tissue. The aim of this study was to find out whether the new hypolipidamic agent CI-719 shared the anti-lipolytic properties of clofibrate on rat adipose tissue.
Materials and Methods
Adipose tissue from epididymal fat pads of Sprague-Dawley rats, weighing about 200 g and fed ad libitum, was used in these experiments. The tissue obtained from several rats was pooled and cut into pieces weighing approximately 50 mg. Two pieces were placed in each incubation flask containing Krebs-Ringer bicarbonate buffer Dr R S Elkeles (pH 7.4) made up with 4 % bovine serum albumin (Fraction V, Armour Pharmaceuticals). Additions of the compounds to be tested were made and the flasks were gassed with 95 % 02, 5 % C02 before they were stoppered. Incubation was carried out at 37°C for 2 h in quadruplicate, so that each observation represents the mean value of four flasks. At the end of the period of incubation the pieces of fat were removed and the lipid was extracted by the method of Folch et al. (1957) . The incubation medium was deproteinized with 10 % trichloracetic acid. After washing with ether. IL, glycerol was measured as an index of lipolysis by an enzymatic method (Boehringer Corporation). Results were expressed as nmol glycerol released/mg lipid per 2 h.
Results
At a concentration of 80 mg/ml we were unable to show an effect of clofibrate on basal lipolysis (Fig 1) . CI-719 on the other hand had a significant inhibitory effect on basal lipolysis. Both drugs had a concentration-dependent effect on isoprenaline stimulated lipolysis (Figs 2 and 3) . The effects on lipolysis stimulated by dibutyryl cyclic AMP (cAMP) are shown in Figs 4 and 5. CI-719 inhibited cAMP stimulated lipolysis at a lower concentration than clofibrate, and the effect appeared greater.
Discussion
These studies suggest that CI-719 inhibits both basal and hormone-stimulated lipolysis in rat adipose tissue. A possible mode of action for clofibrate (summarized by Carlson et al. 1972 ) is that reduced adipose tissue lipolysis leads to decreased plasma FFA levels, which in turn leads to reduced uptake of FFA by the liver and thus decreased hepatic triglyceride synthesis and plasma triglyceride concentration. Assuming this mode of events to be correct, then reduced adipose tissue lipolysis could represent a mechanism for the lipid lowering effect of CI-719. However, these studies require confirmation in human adipose tissue.
